Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 502

1.

Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?

Stefano JT, de Oliveira CP, Corrêa-Giannella ML, Soares IC, Kubrusly MS, Bellodi-Privato M, de Mello ES, de Lima VM, Carrilho FJ, Alves VA.

Liver Int. 2011 Mar;31(3):377-85. doi: 10.1111/j.1478-3231.2010.02370.x. Epub 2010 Nov 26.

PMID:
21108736
2.

Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.

Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH.

Am J Surg Pathol. 2010 Nov;34(11):1630-6. doi: 10.1097/PAS.0b013e3181f31caa.

PMID:
20975341
3.

Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C.

Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K.

J Gastroenterol Hepatol. 2009 Feb;24(2):248-54. doi: 10.1111/j.1440-1746.2008.05640.x. Epub 2008 Nov 20.

PMID:
19032450
4.

Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis.

Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R.

J Hepatol. 2009 Feb;50(2):351-7. doi: 10.1016/j.jhep.2008.09.011. Epub 2008 Nov 14.

PMID:
19070395
6.

Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.

Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL.

Gut. 2010 Jul;59(7):969-74. doi: 10.1136/gut.2009.205088.

PMID:
20581244
7.

Comparison of hepatocellular carcinoma patients with alcoholic liver disease and nonalcoholic steatohepatitis.

Hashimoto E, Taniai M, Kaneda H, Tokushige K, Hasegawa K, Okuda H, Shiratori K, Takasaki K.

Alcohol Clin Exp Res. 2004 Aug;28(8 Suppl Proceedings):164S-168S.

PMID:
15318106
8.

[Two cases of patients with hepatocellular carcinoma (HCC) that developed in cryptogenic cirrhosis suggestive of nonalcoholic steatohepatitis (NASH) as background liver disease after clinical courses of 26 years].

Tsutsumi K, Nakayama H, Sakai Y, Kojima Y, Dairaku N, Ojima T, Kusano M, Ikeya S, Sugai Y, Hiwatashi N.

Nihon Shokakibyo Gakkai Zasshi. 2007 May;104(5):690-7. Japanese.

PMID:
17485950
9.

Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.

Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H.

Am J Gastroenterol. 2012 Feb;107(2):253-61. doi: 10.1038/ajg.2011.327. Epub 2011 Oct 18.

PMID:
22008893
10.

Iron overload in nonalcoholic steatohepatitis.

Fujita N, Takei Y.

Adv Clin Chem. 2011;55:105-32. Review.

PMID:
22126026
11.

Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease.

Ma H, Gomez V, Lu L, Yang X, Wu X, Xiao SY.

J Gastroenterol Hepatol. 2009 Feb;24(2):233-7. doi: 10.1111/j.1440-1746.2008.05548.x. Epub 2008 Aug 17.

PMID:
18713296
12.

[Non-alcoholic fatty liver disease--new view].

Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezyńska-Kurtycz J, Milkiewicz P.

Pol Merkur Lekarski. 2008 Jun;24(144):568-71. Review. Polish.

PMID:
18702346
13.

Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.

Starley BQ, Calcagno CJ, Harrison SA.

Hepatology. 2010 May;51(5):1820-32. doi: 10.1002/hep.23594. Review.

PMID:
20432259
14.

Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma.

Cuadrado A, Orive A, García-Suárez C, Domínguez A, Fernández-Escalante JC, Crespo J, Pons-Romero F.

Obes Surg. 2005 Mar;15(3):442-6. Review.

PMID:
15826485
15.

[Imaging of NASH].

Tanimoto A, Tomita K.

Nihon Rinsho. 2006 Jun;64(6):1127-32. Review. Japanese.

PMID:
16768120
16.

Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.

Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM.

Obes Surg. 2005 Mar;15(3):310-5.

PMID:
15826462
17.

Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.

Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A.

Int J Cancer. 2011 May 15;128(10):2436-43. doi: 10.1002/ijc.25797. Epub 2011 Mar 14.

18.

[Clinical and histological features of non-alcoholic fatty liver disease].

Shi JP, Xun YH, Hu CB, Zhang L, Liu H, Lou GQ, Fan JG.

Zhonghua Gan Zang Bing Za Zhi. 2009 Nov;17(11):812-6. Chinese.

PMID:
19958638
19.

Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.

Koskinas J, Petraki K, Kavantzas N, Rapti I, Kountouras D, Hadziyannis S.

J Viral Hepat. 2005 Nov;12(6):635-41.

PMID:
16255765
20.

Obesity and non-alcoholic fatty liver disease in chronic hepatitis C.

Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, Bringman D, Martin LM, Assmann J, Gramlich T, Mullen KD, O'Shea R, Carey WD, Ferguson R.

J Clin Gastroenterol. 2004 Sep;38(8):705-9.

PMID:
15319656

Supplemental Content

Support Center